Bionexus Gene Lab 's Cash & cash equivalent grew by 34.03 % in the Q2 2026 sequentially, faster than Current Liabilities, this led to improvement in Bionexus Gene Lab 's Quick Ratio to 4.33, Quick Ratio remained below Bionexus Gene Lab Corp average.

Within Medical Laboratories industry 11 other companies have achieved higher Quick Ratio than Bionexus Gene Lab in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 579 to 1067.

Explain Quick Ratio?
How much Cash & cash equivalents BGLC�s has?
What are BGLC�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

BGLC Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	-51.79 %	-46.61 %	-16.76 %	-57.63 %	49.14 %
Y / Y Cash & cash equivalent Change	56.88 %	-26.92 %	-28.89 %	-57.91 %	-58.54 %
Quick Ratio MRQ	4.33	3.3	9.8	3.05	1.33
BGLC's Total Ranking	# 1067	# 579	# 1221	# 2019	# 1459
Seq. Current Liabilities Change	2.06 %	93.15 %	-27.81 %	-66.12 %	13.02 %
Seq. Cash & cash equivalent Change	34.03 %	-34.96 %	131.96 %	-22.42 %	-37.57 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Medical Laboratories Industry	# 12
Healthcare Sector	# 331
Overall Market	# 878

Quick Ratio Statistics
High	Average	Low
68.4	11.78	0.58
(Sep 30 2020)		(Jun 30 2021)

Financial Statements
Bionexus Gene Lab 's Current Liabilities	$ 1 Millions	Visit BGLC's Balance sheet
Bionexus Gene Lab 's Cash & cash equivalent	$ 4 Millions	Visit BGLC's Balance sheet
Source of BGLC's Sales		Visit BGLC's Sales by Geography

Cumulative Bionexus Gene Lab 's Quick Ratio

BGLC's Quick Ratio for the trailling 12 Months

BGLC Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-48.36 %	-22.39 %	-9.88 %	-25.61 %	-15.85 %
Y / Y Cash & cash equivalent TTM Growth	-23.81 %	-43.42 %	-44.83 %	-37.77 %	-32.86 %
Quick Ratio TTM	4.6	3.07	2.79	3.12	3.12
Total Ranking TTM	# 1732	# 1816	# 1473	# 1223	# 944
Seq. Current Liabilities TTM Growth	-25.19 %	-16.71 %	-1.96 %	-15.47 %	12.44 %
Seq. Cash & cash equivalent TTM Growth	11.99 %	-8.33 %	-12.37 %	-15.3 %	-16.83 %

Quick ratio ranking by company, industry and sector >> Back to BGLC Financial Strength Comparisons >> Go to Compare BGLC Quick Ratio to its Competitors

On the trailing twelve months basis BGLC Cash & cash equivalent soared by 56.88 % in Q2 2026 year on year, while Current Liabilities rose to $1 millions, this led to increase in in Bionexus Gene Lab 's Quick Ratio to 4.6, above BGLC average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Laboratories industry 34 other companies have achieved higher Quick Ratio than Bionexus Gene Lab . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 2686.

Explain Quick Ratio?
How much Cash & cash equivalents BGLC�s has?
What are BGLC�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Medical Laboratories Industry	# 35
Healthcare Sector	# 888
Within the Market	# 1067

trailing twelve months Quick Ratio Statistics
High	Average	Low
28.55	3.91	0.23
(Sep 30 2020)		(Sep 30 2021)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Medical Laboratories Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Maxcyte inc	10.68	$ 105.690 Millions	$ 9.895 Millions
Grail Inc	10.29	$ 859.755 Millions	$ 83.542 Millions
Absci Corp	10.12	$ 201.142 Millions	$ 19.878 Millions
Billiontoone Inc	9.85	$ 548.628 Millions	$ 55.725 Millions
Celcuity Inc	8.68	$ 754.000 Millions	$ 86.873 Millions
Veracyte Inc	7.76	$ 487.046 Millions	$ 62.736 Millions
Personalis Inc	6.00	$ 278.411 Millions	$ 46.385 Millions
Castle Biosciences Inc	4.72	$ 266.805 Millions	$ 56.509 Millions
Bionexus Gene Lab Corp	4.33	$ 3.522 Millions	$ 0.813 Millions
Caredx Inc	3.99	$ 373.636 Millions	$ 93.698 Millions
Omniab Inc	3.78	$ 51.995 Millions	$ 13.758 Millions
Fulgent Genetics Inc	3.58	$ 257.032 Millions	$ 71.756 Millions
Guardant Health Inc	3.11	$ 1,053.469 Millions	$ 338.962 Millions
Butterfly Network Inc	2.13	$ 124.659 Millions	$ 58.603 Millions
Natera Inc	1.97	$ 1,091.502 Millions	$ 553.200 Millions
Biodesix Inc	1.96	$ 29.996 Millions	$ 15.291 Millions
Sera Prognostics Inc	1.91	$ 46.445 Millions	$ 24.356 Millions
Exagen Inc	1.83	$ 24.588 Millions	$ 13.457 Millions
Radnet Inc	1.11	$ 773.510 Millions	$ 697.822 Millions
Bioaffinity Technologies Inc	0.91	$ 2.430 Millions	$ 2.681 Millions

Date modified: 2026-08-17T17:18:54+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.